Gill G V, Rauf O, MacFarlane I A
Department of Medicine, Walton Hospital, Liverpool, UK.
Postgrad Med J. 1997 Oct;73(864):640-1. doi: 10.1136/pgmj.73.864.640.
A survey of UK patients receiving the drug diazoxide, revealed 40 patients with insulinoma on this treatment. Mean age (+/- SD) was 67 +/- 18 years, and 74% were female. Duration of treatment was 7 +/- 6 years (range 1-22). Most (55%) patients were treated with diazoxide because of tumour non-localisation (including failed previous surgery). Metastatic disease (20%) and poor surgical risk (10%) were other indications. Side-effects (notably fluid retention and hirsutism) were common (47%) but not troublesome. Treatment was highly effective--59% were symptom free and 38% had only occasional symptoms. Only one patient had frequent hypoglycaemia despite treatment. We conclude that diazoxide is effective in the management of insulinoma. Side-effects are common but not problematic. Treatment should be considered for all patients not cured by surgery, or unsuitable for surgical treatment.
一项针对接受二氮嗪治疗的英国患者的调查显示，有40名患有胰岛素瘤的患者接受了这种治疗。平均年龄（±标准差）为67±18岁，74%为女性。治疗持续时间为7±6年（范围1 - 22年）。大多数（55%）患者因肿瘤无法定位（包括先前手术失败）而接受二氮嗪治疗。转移性疾病（20%）和手术风险高（10%）是其他适应症。副作用（尤其是液体潴留和多毛症）很常见（47%）但并不麻烦。治疗非常有效——59%的患者无症状，38%的患者仅偶尔出现症状。尽管接受了治疗，但只有一名患者频繁发生低血糖。我们得出结论，二氮嗪在胰岛素瘤的治疗中是有效的。副作用很常见但没有问题。对于所有未通过手术治愈或不适合手术治疗的患者，都应考虑进行该治疗。
